RxDoctor Payments Data

Matthew Beelen, MD

Geriatric Medicine · Lancaster, PANPI 1770548216

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Lilly USA, LLC at 31.9% of the total.

$588in general payments, 2019–2025

Across 18 payments — averaging $32.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$187
  • Eisai Inc.$174
  • Otsuka America Pharmaceutical, Inc.$125
  • Biogen$55
  • EMD Serono, Inc.$24
  • Corium, LLC$23

What the payments were for

  • Food & beverage$56295%
  • Education$275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$588 in reported general payments places this provider in the 75th percentile of 217 geriatric medicine providers in Pennsylvania.

See all geriatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$114,141
Medicare patients
432
Services billed
1,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$78,561
JardianceEmpagliflozin20$22,114
MyrbetriqMirabegron29$16,522
XareltoRivaroxaban36$14,235
Memantine Hcl240$8,208
Rivastigmine60$6,868
Donepezil Hcl433$3,980
Aripiprazole56$2,919
Mirtazapine168$2,633
RivastigmineRivastigmine Tartrate40$2,607
LantusInsulin Glargine,hum.Rec.Anlog34$2,562
Escitalopram Oxalate225$2,472
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,141
Duloxetine Hcl58$2,122
Omeprazole148$1,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCHumalog$187$1,04114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 217 geriatric medicine providers in Pennsylvania.

Other geriatric medicine in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →